Abstract
Schistosomiasis is a zoonotic and debilitating parasitic disease caused by Schistosoma japonicum. Praziquantel remains the choice for treating schistosomiasis, but its efficacy could be hampered by emergence of resistance. In this study, using large-scale drug screening, we selected out myricetin, a natural flavonol compound, having a good anti-schistosome effect. We found that myricetin exhibited dose and time-dependent insecticidal effect on S. japonicum in vitro, with an LC50 of 600 μM for 24 h, and inhibited female spawning. The drug mainly destroyed the body structure of the worms and induced apoptosis of the worm cells, which in turn led to death. In addition, oral administration of myricetin in mice infected with S. japonicum showed a deworming effect in vivo, as evidenced by a significant reduction in the liver egg load. H&E staining, quantitative RT-PCR, and Western blotting assays showed that myricetin significantly alleviated liver fibrosis in mice infected with S. japonicum. Myricetin also effectively inhibited the expression of TGFβ1, Smad2, phospho-Smad2, Smad3, phospho-Smad3, ERK, phospho-ERK, Akt, and phospho-Akt in the liver of infected mice, suggesting that myricetin attenuated liver fibrosis in mice via modulating TGFβ1 and Akt signaling. Flow cytometric analysis of Th subtypes (Th1/Th2/Th17/Treg) in the mouse spleen further revealed that myricetin significantly increased the percentage Th1 cells in infected mice and reduced the proportion of Th2 cells and Th17 cells. Immunology multiplex assay further showed that myricetin attenuated S. japonicum-induced rise in the plasma levels of IL-4, IL-5, IL-10, IL-13, and IL-17A in infected mice while increasing the plasma contents of IFN-γ, IL-12, and IL-7. In conclusion, our study provides the first direct evidence that myricin possesses potent anti-schistosome activities in vitro and in vivo, and offers new insights into the mechanisms of action by myricetin. The present findings suggest that myricetin could be further explored as a therapeutic agent for S. japonicum.
Highlights
Schistosomiasis is a parasitic disease caused by parasites of the genus Schistosoma
We further examined the expression of α-SMA, collagen I and IV in liver tissue
Our RT-PCR assays showed that myricetin caused a 10, 6, and 4.6-fold reduction in the mRNA transcript levels of α-SMA, collagen I and IV in infected mice compared to nontreated infected mice [F(3, 8) = 19.81, P < 0.001]; F(3, 8) = 5.63, P = 0.04 and F(3, 8) = 15.5, P = 0.002, respectively) (Figure 9A)
Summary
Schistosomiasis is a parasitic disease caused by parasites of the genus Schistosoma. According to a World Health Organization survey, schistosomiasis, one of the neglected tropical diseases, is endemic in 78 countries and regions, infecting ∼230 million people and posing a health threat to ∼780 million people worldwide. There are mainly six species of schistosomiasis that are related to humans, of which Schistosoma (S.) mansoni, S. haematobium, and S.japonicum are the most prevalent [4]. Schistosomiasis cannot proliferate in the final host, it can produce a large number of eggs deposited in the liver or other organs. Mature females can lay hundreds (S. mansoni, S. haematobium) to thousands (S. japonicum) of eggs per day. Longterm parasitism and massive egg production leads to infection and disease transmission
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have